300966 共同药业
交易中 09-22 10:57:18
资讯
新帖
简况
股市必读：共同药业新发布《关于持股5%以上股东、董事减持计划期限届满暨减持结果的公告》
证券之星 · 09-14
股市必读：共同药业新发布《关于持股5%以上股东、董事减持计划期限届满暨减持结果的公告》
中银证券：给予共同药业买入评级
证券之星 · 08-31
中银证券：给予共同药业买入评级
共同药业（300966）2026年中报简析：增收不增利，短期债务压力上升
证券之星 · 08-27
共同药业（300966）2026年中报简析：增收不增利，短期债务压力上升
股市必读：共同药业新发布《2026年半年度报告摘要》
证券之星 · 08-27
股市必读：共同药业新发布《2026年半年度报告摘要》
共同药业(300966.SZ)发布上半年业绩，归母净亏损3284.13万元
智通财经 · 08-25
共同药业(300966.SZ)发布上半年业绩，归母净亏损3284.13万元
图解共同药业中报：第二季度单季净利润同比下降194.57%
证券之星 · 08-25
图解共同药业中报：第二季度单季净利润同比下降194.57%
共同药业：8月13日董事李明磊增持股份合计7000股
证券之星 · 08-14
共同药业：8月13日董事李明磊增持股份合计7000股
股市必读：共同药业（300966）7月23日董秘有最新回复
证券之星 · 07-24
股市必读：共同药业（300966）7月23日董秘有最新回复
共同药业：公司生产经营活动一切正常
证券之星 · 07-23
共同药业：公司生产经营活动一切正常
共同药业（300966）披露2025年度权益分派实施公告，7月9日股价下跌1.89%
证券之星 · 07-09
共同药业（300966）披露2025年度权益分派实施公告，7月9日股价下跌1.89%
共同药业（300966）披露股东权益变动报告书，7月7日股价上涨2.18%
证券之星 · 07-07
共同药业（300966）披露股东权益变动报告书，7月7日股价上涨2.18%
共同药业：7月1日董事李明磊增持股份合计10.84万股
证券之星 · 07-02
共同药业：7月1日董事李明磊增持股份合计10.84万股
共同药业（300966）披露2025年度可转换公司债券受托管理事务报告，7月1日股价上涨2.91%
证券之星 · 07-01
共同药业（300966）披露2025年度可转换公司债券受托管理事务报告，7月1日股价上涨2.91%
共同药业：6月26日董事李明磊减持股份合计7000股
证券之星 · 06-29
共同药业：6月26日董事李明磊减持股份合计7000股
共同药业（300966）披露主体及共同转债2026年度跟踪评级报告，6月29日股价下跌2.34%
证券之星 · 06-29
共同药业（300966）披露主体及共同转债2026年度跟踪评级报告，6月29日股价下跌2.34%
共同药业：6月25日董事李明磊减持股份合计230.56万股
证券之星 · 06-26
共同药业：6月25日董事李明磊减持股份合计230.56万股
股市必读：6月25日共同药业现6160.61万元大宗交易
证券之星 · 06-26
股市必读：6月25日共同药业现6160.61万元大宗交易
每周股票复盘：共同药业（300966）完成集团化更名
证券之星 · 06-21
每周股票复盘：共同药业（300966）完成集团化更名
共同药业（300966）披露完成公司名称变更并换发营业执照的公告，6月16日股价下跌2.94%
证券之星 · 06-16
共同药业（300966）披露完成公司名称变更并换发营业执照的公告，6月16日股价下跌2.94%
共同药业（300966）披露持股5%以上股东、董事减持股份预披露公告，5月21日股价下跌0.19%
证券之星 · 05-21
共同药业（300966）披露持股5%以上股东、董事减持股份预披露公告，5月21日股价下跌0.19%
公司概况
公司名称：
湖北共同药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2021-04-09
主营业务：
湖北共同药业集团股份有限公司的主营业务是甾体药物原料的研发、生产及销售。公司的主要产品是雄烯二酮（AD）、雄二烯二酮（ADD）、双降醇（BA）、9-羟基雄烯二酮（9OH-AD）。
发行价格：
8.24
{"stockData":{"symbol":"300966","market":"SZ","secType":"STK","nameCN":"共同药业","latestPrice":26.21,"timestamp":1790045838000,"preClose":25.88,"halted":0,"volume":1951403,"delay":0,"changeRate":0.0128,"floatShares":76666700,"shares":114999999,"eps":-0.8245,"marketStatus":"交易中","change":0.33,"latestTime":"09-22 10:57:18","open":25.74,"high":26.25,"low":25.57,"amount":50437200,"amplitude":0.0263,"askPrice":26.21,"askSize":23,"bidPrice":26.18,"bidSize":1,"shortable":0,"etf":0,"ttmEps":-0.8245,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1790047800000},"marketStatusCode":2,"adr":0,"adjPreClose":25.88,"symbolType":"stock","openAndCloseTimeList":[[1790040600000,1790047800000],[1790053200000,1790060400000]],"highLimit":28.47,"lowLimit":23.29,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":115281113,"isCdr":false,"pbRate":4.27,"roa":"--","roe":"--","epsLYR":-0.64,"committee":-0.608511,"marketValue":3022000000,"turnoverRate":0.0255,"status":0,"floatMarketCap":2009000000},"requestUrl":"/m/hq/s/300966/wiki","defaultTab":"wiki","newsList":[{"id":"2667287638","title":"股市必读：共同药业新发布《关于持股5%以上股东、董事减持计划期限届满暨减持结果的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2667287638","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667287638?lang=zh_cn&edition=full","pubTime":"2026-09-14 03:56","pubTimestamp":1789329373,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，共同药业报收于23.0元，上涨0.35%，换手率2.65%，成交量2.04万手，成交额4634.53万元。公司公告汇总：持股5%以上股东、董事李明磊减持计划期限届满，通过大宗交易减持2,197,222股，减持后持股比例为10.0000%。交易信息汇总资金流向9月11日主力资金净流出145.5万元，占总成交额3.14%；游资资金净流入474.21万元，占总成交额10.23%；散户资金净流出328.72万元，占总成交额7.09%。减持后李明磊合计持有股份11,528,078股，占总股本10.0000%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400001698.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663191074","title":"中银证券：给予共同药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2663191074","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663191074?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:19","pubTimestamp":1788171568,"startTime":"0","endTime":"0","summary":"中银国际证券股份有限公司刘恩阳,苏雪儿近期对共同药业进行研究并发布了研究报告《营收保持增长，静待产能爬坡与盈利修复》，给予共同药业买入评级。随着公司新布局高端原料药业务逐步落地，产能利用率提升，海外业务拓展持续深化，公司收入有望保持稳定增长，维持买入评级。最新盈利预测明细如下：该股最近90天内共有1家机构给出评级，买入评级1家。本文数据来源于中银国际证券股份有限公司，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100026518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966","601696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662728143","title":"共同药业（300966）2026年中报简析：增收不增利，短期债务压力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2662728143","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662728143?lang=zh_cn&edition=full","pubTime":"2026-08-27 06:48","pubTimestamp":1787784517,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期共同药业发布2026年中报。截至本报告期末，公司营业总收入3.46亿元，同比上升14.51%，归母净利润-3284.13万元，同比下降194.47%。本报告期共同药业短期债务压力上升，流动比率达0.93。本次财报公布的各项数据指标表现一般。融资分红：公司上市5年以来，累计融资总额2.39亿元，累计分红总额2270.98万元，分红融资比为0.1。本文数据来源于共同药业2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700013485.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662744104","title":"股市必读：共同药业新发布《2026年半年度报告摘要》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662744104","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662744104?lang=zh_cn&edition=full","pubTime":"2026-08-27 04:22","pubTimestamp":1787775731,"startTime":"0","endTime":"0","summary":"截至2026年8月26日收盘，共同药业报收于24.32元，下跌1.98%，换手率5.95%，成交量4.56万手，成交额1.1亿元。公司公告汇总：2026年半年度报告摘要显示，营业收入同比增长14.51%，但归母净利润为-3284.13万元，同比减少194.47%；经营活动现金流量净额同比增长487.99%。公司公告汇总：截至2026年上半年末，非经营性资金占用期末余额合计为34,546.92万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700009735.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662731952","title":"共同药业(300966.SZ)发布上半年业绩，归母净亏损3284.13万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662731952","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662731952?lang=zh_cn&edition=full","pubTime":"2026-08-25 19:42","pubTimestamp":1787658172,"startTime":"0","endTime":"0","summary":"智通财经APP讯，共同药业(300966.SZ)发布2026年半年度报告，报告期内，公司实现营业收入3.46亿元，同比增长14.51%。归属于上市公司股东净亏损3284.13万元，归属于上市公司股东的扣除非经常性损益净亏损3266.54万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1485290.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662356807","title":"图解共同药业中报：第二季度单季净利润同比下降194.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662356807","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662356807?lang=zh_cn&edition=full","pubTime":"2026-08-25 18:24","pubTimestamp":1787653473,"startTime":"0","endTime":"0","summary":"证券之星消息，共同药业2026年中报显示，上半年度公司主营收入3.46亿元，同比上升14.51%；归母净利润-3284.13万元，同比下降194.47%；扣非净利润-3266.54万元，同比下降219.65%；其中2026年第二季度，公司单季度主营收入1.84亿元，同比上升12.96%；单季度归母净利润-3603.98万元，同比下降194.57%；单季度扣非净利润-3595.65万元，同比下降211.16%；负债率69.96%，投资收益-409.58万元，财务费用2855.92万元，毛利率14.08%。财报数据概要请见下图:本文数据来源于共同药业2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500039144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659144349","title":"共同药业：8月13日董事李明磊增持股份合计7000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2659144349","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659144349?lang=zh_cn&edition=full","pubTime":"2026-08-14 21:01","pubTimestamp":1786712474,"startTime":"0","endTime":"0","summary":"证券之星消息，根据8月14日市场公开信息、上市公司公告及交易所披露数据整理，共同药业最新董监高及相关人员股份变动情况：2026年8月13日公司董事,高管李明磊共增持公司股份7000.0股，占公司总股本为0.0061%。变动期间公司股价下跌1.73%，8月13日当日收盘报26.71元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400037836.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653720452","title":"股市必读：共同药业（300966）7月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2653720452","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653720452?lang=zh_cn&edition=full","pubTime":"2026-07-24 02:43","pubTimestamp":1784832190,"startTime":"0","endTime":"0","summary":"截至2026年7月23日收盘，共同药业报收于23.0元，上涨6.38%，换手率6.71%，成交量5.14万手，成交额1.14亿元。董秘最新回复投资者： 尊敬的董秘，近期创新药板块都是大涨，公司股价前期涨幅且不是很大，近期市场大跌，公司股价也跟随大跌，公司层面出现了问题了吗？","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400001800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653717310","title":"共同药业：公司生产经营活动一切正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2653717310","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653717310?lang=zh_cn&edition=full","pubTime":"2026-07-23 15:51","pubTimestamp":1784793066,"startTime":"0","endTime":"0","summary":"证券之星消息，共同药业07月23日在投资者关系平台上答复投资者关心的问题。感谢对共同药业的关注，谢谢!","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300028283.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650916940","title":"共同药业（300966）披露2025年度权益分派实施公告，7月9日股价下跌1.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650916940","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650916940?lang=zh_cn&edition=full","pubTime":"2026-07-09 17:18","pubTimestamp":1783588692,"startTime":"0","endTime":"0","summary":"截至2026年7月9日收盘，共同药业报收于29.1元，较前一交易日下跌1.89%，最新总市值为33.55亿元。该股当日开盘29.15元，最高30.72元，最低28.04元，成交额达2.03亿元，换手率为9.03%。近日，湖北共同药业集团股份有限公司披露《2025年度权益分派实施公告》。本次权益分派股权登记日为2026年7月15日，除权除息日为2026年7月16日。公司回购专用证券账户中的股份不参与本次权益分派。本次权益分派实施后，“共同转债”转股价格由27.12元/股调整为27.08元/股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900030316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649985025","title":"共同药业（300966）披露股东权益变动报告书，7月7日股价上涨2.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649985025","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649985025?lang=zh_cn&edition=full","pubTime":"2026-07-07 17:29","pubTimestamp":1783416569,"startTime":"0","endTime":"0","summary":"截至2026年7月7日收盘，共同药业报收于30.03元，较前一交易日上涨2.18%，最新总市值为34.62亿元。近日，公司披露《简式权益变动报告书》。公告显示，股东李明磊因自身资金需求，于2026年6月25日至7月6日通过集中竞价及大宗交易方式累计减持公司股份2,197,222股，占公司总股本的1.9060%。本次权益变动后，其持股比例由11.9059%降至10.0000%，持有股份11,528,078股。李明磊非公司控股股东或实际控制人，本次减持不会导致公司控制权变更，也不影响公司治理结构及持续经营。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700029743.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648850000","title":"共同药业：7月1日董事李明磊增持股份合计10.84万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648850000","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648850000?lang=zh_cn&edition=full","pubTime":"2026-07-02 21:02","pubTimestamp":1782997337,"startTime":"0","endTime":"0","summary":"证券之星消息，根据7月2日市场公开信息、上市公司公告及交易所披露数据整理，共同药业（300966）最新董监高及相关人员股份变动情况：2026年7月1日公司董事,高管李明磊共增持公司股份10.84万股，占公司总股本为0.094%。变动期间公司股价上涨2.91%，7月1日当日收盘报28.31元。共同药业近半年内的董监高及核心技术人员增减持详情如下：共同药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入1382.07万，融资余额增加；融券净流入0.0，融券余额增加。该股最近90天内无机构评级。本文数据来源于深圳证券交易所信息披露、共同药业公告，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200040050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648511142","title":"共同药业（300966）披露2025年度可转换公司债券受托管理事务报告，7月1日股价上涨2.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648511142","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648511142?lang=zh_cn&edition=full","pubTime":"2026-07-01 17:49","pubTimestamp":1782899344,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘，共同药业报收于28.31元，较前一交易日上涨2.91%，最新总市值为32.64亿元。该股当日开盘27.6元，最高29.18元，最低26.0元，成交额达2.11亿元，换手率为9.94%。近日，湖北共同药业集团股份有限公司发布《向不特定对象发行可转换公司债券受托管理事务报告》。2025年11月完成第三年付息，票面利率1.10%。东方金诚于2025年6月将公司主体及可转债信用等级由A+下调至A，2026年6月进一步下调至A-。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100034634.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647374210","title":"共同药业：6月26日董事李明磊减持股份合计7000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647374210","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647374210?lang=zh_cn&edition=full","pubTime":"2026-06-29 21:02","pubTimestamp":1782738122,"startTime":"0","endTime":"0","summary":"证券之星消息，根据6月29日市场公开信息、上市公司公告及交易所披露数据整理，共同药业（300966）最新董监高及相关人员股份变动情况：2026年6月26日公司董事,高管李明磊共减持公司股份7000.0股，占公司总股本为0.0061%。变动期间公司股价下跌3.82%，6月26日当日收盘报28.18元。共同药业近半年内的董监高及核心技术人员增减持详情如下：共同药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入1064.9万，融资余额增加；融券净流入0.0，融券余额增加。该股最近90天内无机构评级。本文数据来源于深圳证券交易所信息披露、共同药业公告，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900038236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647378844","title":"共同药业（300966）披露主体及共同转债2026年度跟踪评级报告，6月29日股价下跌2.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647378844","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647378844?lang=zh_cn&edition=full","pubTime":"2026-06-29 17:54","pubTimestamp":1782726869,"startTime":"0","endTime":"0","summary":"截至2026年6月29日收盘，共同药业报收于27.52元，较前一交易日下跌2.34%，最新总市值为31.73亿元。近日，湖北共同药业集团股份有限公司披露《湖北共同药业集团股份有限公司主体及共同转债2026年度跟踪评级报告》。东方金诚国际信用评估有限公司对湖北共同药业集团股份有限公司及“共同转债”进行跟踪评级，下调公司主体信用等级为A-，评级展望维持稳定，同时下调“共同转债”信用等级为A-。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900028366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646350997","title":"共同药业：6月25日董事李明磊减持股份合计230.56万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646350997","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646350997?lang=zh_cn&edition=full","pubTime":"2026-06-26 21:01","pubTimestamp":1782478919,"startTime":"0","endTime":"0","summary":"证券之星消息，根据6月26日市场公开信息、上市公司公告及交易所披露数据整理，共同药业（300966）最新董监高及相关人员股份变动情况：2026年6月25日公司董事,高管李明磊共减持公司股份230.56万股，占公司总股本为2.0%。变动期间公司股价上涨0.86%，6月25日当日收盘报29.3元。共同药业近半年内的董监高及核心技术人员增减持详情如下：共同药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入907.65万，融资余额增加；融券净流入0.0，融券余额增加。该股最近90天内无机构评级。本文数据来源于深圳证券交易所信息披露、共同药业公告，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600043052.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646260800","title":"股市必读：6月25日共同药业现6160.61万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2646260800","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646260800?lang=zh_cn&edition=full","pubTime":"2026-06-26 02:06","pubTimestamp":1782410773,"startTime":"0","endTime":"0","summary":"截至2026年6月25日收盘，共同药业报收于29.3元，上涨0.86%，换手率13.37%，成交量10.25万手，成交额2.89亿元。当日关注点交易信息汇总：6月25日共同药业发生6160.61万元大宗交易。交易信息汇总资金流向6月25日主力资金净流入1291.26万元，占总成交额0.0%；游资资金净流入1917.04万元，占总成交额0.0%；散户资金净流出3208.3万元，占总成交额0.0%。大宗交易6月25日共同药业现6160.61万元大宗交易。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600001055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645967670","title":"每周股票复盘：共同药业（300966）完成集团化更名","url":"https://stock-news.laohu8.com/highlight/detail?id=2645967670","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645967670?lang=zh_cn&edition=full","pubTime":"2026-06-21 03:38","pubTimestamp":1781984292,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，共同药业报收于26.69元，较上周的26.57元上涨0.45%。本周，共同药业6月15日盘中最高价报27.74元。公司名称由“湖北共同药业股份有限公司”变更为“湖北共同药业集团股份有限公司”。公司已完成工商变更登记，并取得襄阳市市场监督管理局换发的营业执照。证券代码“300966”及证券简称“共同药业”保持不变。本次更名旨在落实集团化发展战略，提升经营管理效能。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100001235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643575955","title":"共同药业（300966）披露完成公司名称变更并换发营业执照的公告，6月16日股价下跌2.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643575955","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643575955?lang=zh_cn&edition=full","pubTime":"2026-06-16 18:52","pubTimestamp":1781607141,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘，共同药业报收于26.39元，较前一交易日下跌2.94%，最新总市值为30.42亿元。近日，共同药业发布《关于完成公司名称变更并换发营业执照的公告》。公告显示，湖北共同药业股份有限公司于2026年4月27日和5月19日分别召开第三届董事会第十三次会议及2025年年度股东会，审议通过变更公司名称并修订《公司章程》的议案。公司证券代码“300966”及证券简称“共同药业”保持不变。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600036689.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637974384","title":"共同药业（300966）披露持股5%以上股东、董事减持股份预披露公告，5月21日股价下跌0.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637974384","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637974384?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:00","pubTimestamp":1779357648,"startTime":"0","endTime":"0","summary":"近日，共同药业发布《关于持股5%以上股东、董事减持股份预披露公告》。公告显示，公司持股5%以上股东、董事李明磊持有公司股份13,725,300股，占公司总股本的12.0174%，因自身资金需要，拟自公告之日起15个交易日后的3个月内，通过集中竞价和/或大宗交易方式减持不超过3,426,345股，即不超过公司总股本的3%。李明磊承诺履行情况良好，本次减持符合其此前披露的持股意向和承诺。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100035610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1790045840269,"stockEarnings":[{"period":"1week","weight":0.1366},{"period":"1month","weight":0.0282},{"period":"3month","weight":-0.1639},{"period":"6month","weight":0.2539},{"period":"1year","weight":0.2033},{"period":"ytd","weight":0.3163}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":0.0114},{"period":"3month","weight":-0.0381},{"period":"6month","weight":0.0046},{"period":"1year","weight":0.034},{"period":"ytd","weight":-0.0048}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖北共同药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"11466人(较上一季度减少3.06%)","perCapita":"6686股","listingDate":"2021-04-09","address":"湖北省襄阳市宜城市小河镇高坑一组","registeredCapital":"11528万元","survey":" 湖北共同药业集团股份有限公司的主营业务是甾体药物原料的研发、生产及销售。公司的主要产品是雄烯二酮（AD）、雄二烯二酮（ADD）、双降醇（BA）、9-羟基雄烯二酮（9OH-AD）。","listedPrice":8.24},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"共同药业(300966)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供共同药业(300966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"共同药业,300966,共同药业股票,共同药业股票老虎,共同药业股票老虎国际,共同药业行情,共同药业股票行情,共同药业股价,共同药业股市,共同药业股票价格,共同药业股票交易,共同药业股票购买,共同药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"共同药业(300966)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供共同药业(300966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}